Browsing: Zelpultide Alfa

ATLANTA, Sept. 29, 2026 /PRNewswire/ — Airway Therapeutics, Inc., a late-stage clinical biopharmaceutical company developing novel biologic therapies for respiratory, inflammatory, and infectious diseases, today announced that it has been awarded a $1.9 million grant (R44HL186892) from the National Institutes

ATLANTA, Aug. 25, 2026 /PRNewswire/ — Airway Therapeutics, Inc., a late-stage clinical biopharmaceutical company developing novel biologic therapies for respiratory, inflammatory, and infectious diseases, today announced the closing of a $50 million equity round to support the continued late-stage clinical